Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Alpha Radiation Emitters Device (DaRT) for the Treatment of of Malignant Cutaneous Tumors

NCT: NCT04068155 · RECRUITING

NCT IDNCT04068155
StatusRECRUITING
Start Date2022-04-01
Completion2028-01
SponsorAlpha Tau Medical LTD. (INDUSTRY)
First posted
Last updated

Brief Summary

A unique approach for cancer treatment employing intratumoral diffusing alpha radiation emitter device for Malignant Cutaneous Tumors

Frequently Asked Questions

What is Alpha Radiation Emitters Device (DaRT) for the Treatment of of Malignant Cutaneous Tumors?

Alpha Radiation Emitters Device (DaRT) for the Treatment of of Malignant Cutaneous Tumors is a clinical trial registered under NCT04068155. Current status: RECRUITING.

What is the status of NCT04068155?

The current status of NCT04068155 (Alpha Radiation Emitters Device (DaRT) for the Treatment of of Malignant Cutaneous Tumors) is: RECRUITING.

When did Alpha Radiation Emitters Device (DaRT) for the Treatment of of Malignant Cutaneous Tumors start?

Alpha Radiation Emitters Device (DaRT) for the Treatment of of Malignant Cutaneous Tumors started on 2022-04-01.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑